These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19878259)

  • 21. Review of the therapeutic uses of liraglutide.
    Ryan GJ; Foster KT; Jobe LJ
    Clin Ther; 2011 Jul; 33(7):793-811. PubMed ID: 21741090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M
    J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early clinical studies with liraglutide.
    Schmidt WE
    Int J Clin Pract Suppl; 2010 Oct; (167):12-20. PubMed ID: 20887300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Liraglutide and glimepiride on glycaemic control in type 2 diabetes in the Mexican cohort (LEAD 3)].
    García-Hernández P; Arechavaleta-Granell Mdel R; Yamamoto J; Falahati A; González-Gálvez G;
    Rev Med Inst Mex Seguro Soc; 2010; 48(5):543-8. PubMed ID: 21205505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.
    Davies MJ; Kela R; Khunti K
    Diabetes Obes Metab; 2011 Mar; 13(3):207-20. PubMed ID: 21205109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
    Jahn E; Sausele T
    Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
    Bode B
    Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2014 Dec; 74(18):2161-74. PubMed ID: 25367717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
    Reboldi G
    G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.
    Henry RR; Buse JB; Sesti G; Davies MJ; Jensen KH; Brett J; Pratley RE
    Endocr Pract; 2011; 17(6):906-13. PubMed ID: 22193143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.
    Fonseca VA; Devries JH; Henry RR; Donsmark M; Thomsen HF; Plutzky J
    J Diabetes Complications; 2014; 28(3):399-405. PubMed ID: 24561125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.
    Armstrong MJ; Houlihan DD; Rowe IA; Clausen WH; Elbrønd B; Gough SC; Tomlinson JW; Newsome PN
    Aliment Pharmacol Ther; 2013 Jan; 37(2):234-42. PubMed ID: 23163663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liraglutide: effects beyond glycaemic control in diabetes treatment.
    McGill JB
    Int J Clin Pract Suppl; 2010 Oct; (167):28-34. PubMed ID: 20887302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B
    Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
    Bode BW; Testa MA; Magwire M; Hale PM; Hammer M; Blonde L; Garber A;
    Diabetes Obes Metab; 2010 Jul; 12(7):604-12. PubMed ID: 20590735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liraglutide (Victoza) for type 2 diabetes.
    Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of liraglutide.
    Jeong KH; Yoo BK
    Int J Clin Pharm; 2011 Oct; 33(5):740-9. PubMed ID: 21952951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.